SCHEMBL6310959

SCHEMBL6310959

CCc1c(C)c(C#N)c2nc3ccccn3c2c1C1=CC(N)CC1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.35
NPSR1 Q6W5P4 2/20 0.33
MAPT P10636 2/20 0.32
NPC1 O15118 1/20 0.32
LMNA P02545 1/20 0.32
RAB9A P51151 1/20 0.32
MDM2 Q00987 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GAA P10253 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MEN1 O00255 1/20 0.32
HK1 P19367 1/20 0.32
KMT2A Q03164 1/20 0.32
HKDC1 Q2TB90 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31
PIK3CD O00329 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6313782 0.80 KDM4E (0.31) KDM4E
SCHEMBL6310328 0.76 NPSR1 (0.44) KDM4ENPSR1MAPTNPC1LMNA
SCHEMBL6311550 0.69 KDM4E (0.48) KDM4ENPSR1MAPTNPC1LMNA
SCHEMBL6312086 0.69 MAPT (0.47) KDM4ENPSR1MAPTNPC1LMNA
SCHEMBL6317933 0.68 ADORA1 (0.38) KDM4ENPSR1MAPTNPC1LMNA
SCHEMBL6311562 0.68 HPGD (0.43) KDM4ENPSR1MAPTNPC1LMNA
SCHEMBL6310742 0.68 HPGD (0.43) KDM4ENPSR1MAPTNPC1LMNA
SCHEMBL6312805 0.67 HSD17B10 (0.43) KDM4ENPSR1MAPTRAB9ASMN1; SMN2
SCHEMBL6312786 0.67 KDM4E (0.44) KDM4ENPSR1MAPTNPC1LMNA
SCHEMBL6311163 0.67 CKS1B (0.36) KDM4EMAPTTDP1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-05-26 US disclosed
EP-1479681-A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113397-A1 Imidazo[1,2-a]pyridine derivative MANBA, MAN2B1, ERG28 KDM4E 3360/4885NPSR1 1531/4885MAPT 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.